Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check7 days agoChange DetectedNo significant changes to core content or time-sensitive information detected; updates appear to be only date-related entries and deletions of some earlier dates.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange Detected- Location designation updated from Rhône-Alpes to Auvergne-Rhône-Alpes for Lyon with postal code unchanged. - Revision bumped from v3.1.0 to v3.2.0. - Added general government-operating-status notice (lower impact).SummaryDifference4%

- Check29 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0, updating the page revision/version metadata.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page is updated to v3.0.2 from v3.0.1, and the 'Back to Top' element was removed.SummaryDifference0.1%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.1%

- Check57 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous locations across various countries and the inclusion of detailed drug information for specific medications. Notably, the facility name and location have been added, enhancing the core content of the page.SummaryDifference24%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.